How to get retatrutide, an investigational drug: through a clinical trial, or through expanded access when a trial is not possible.1,2 Expanded access is a potential pathway for a patient with a serious or life-threatening condition who cannot join a trial and has no comparable or satisfactory therapy.2
The Food and Drug Administration (FDA) says retatrutide is not a component of any FDA-approved drug and has not been found safe and effective for any condition.3
In one trial, people on the highest retatrutide dose, 12 mg, lost weight over 80 weeks: their average change in body weight was -25.0%, against -3.9% on placebo.4 The trial, TRIUMPH-1, enrolled 2339 adults with obesity and without diabetes and was published in the New England Journal of Medicine.4
Results vary from person to person, and trial averages are not a forecast of any one person’s result.
Key takeaways
- Not approved: retatrutide is considered an investigational drug, and federal law bars pharmacies from compounding it.3,1,2
- Two routes: a clinical trial whenever possible, or, when a trial is not possible, expanded access, which a licensed physician, an institutional review board (IRB) and the company must all agree to.2
- Research-labeled products: the FDA has warned companies that sold retatrutide falsely labeled “for research purposes”, and urges consumers not to buy such products.3
- Available now: semaglutide and tirzepatide, which lowered body weight more than placebo in trials of adults with overweight or obesity without diabetes.5,6,7,8
If you would rather not wait for retatrutide, a Telezen MD GLP-1 plan includes a physician consultation and compounded GLP-1 medication. Like every compounded drug, the plan’s medication is not FDA approved.3
How to Get Retatrutide Right Now
Where to get retatrutide, an investigational drug: in a clinical trial, or through expanded access when a trial is not possible.1,2 The FDA says an investigational product should be used as part of a clinical trial whenever possible.2
An investigational product is a drug, biologic or device that is still being tested to see whether it is safe and effective.2
- A clinical trial: you can search for trials with the FDA’s clinical trials search tool or on ClinicalTrials.gov.2
- Expanded access: when a patient cannot join a trial, for example because none is nearby or they are not eligible, expanded access may be the only way to receive an investigational product.2
- Not a pharmacy or a website: the FDA has warned companies that illegally sold drugs containing retatrutide.3
Is Retatrutide FDA Approved?
No: retatrutide is not FDA approved for any condition, and Lilly is still testing its safety and efficacy in clinical trials.3,1
Retatrutide is a triple-receptor agonist: one molecule that acts on the receptors for three hormones, glucose-dependent insulinotropic polypeptide (GIP), GLP-1 and glucagon.4 GLP-1 is a natural hormone that your gut releases after a meal. In its trials, retatrutide was given as a once-weekly injection under the skin.4,9,10
How Much Weight Did People Lose on Retatrutide?
On the highest retatrutide dose, body weight changed by an average of -25.0% over 80 weeks in TRIUMPH-1, in adults with obesity without diabetes, and -24.2% over 48 weeks in a phase II trial, against -3.9% and -2.1% on placebo.4,9 Retatrutide lowered body weight more than placebo in four randomized trials, in adults with obesity and in adults with diabetes.9,4,11,12
| Trial | Who took part | Dose shown | Length | Average change in body weight | With placebo | Published as |
|---|---|---|---|---|---|---|
| TRIUMPH-1 | 2339 adults with obesity, without diabetes | 12 mg | 80 weeks | -25.0% | -3.9% | Peer-reviewed paper, New England Journal of Medicine4 |
| Phase II trial | People with obesity | 12 mg | 48 weeks | -24.2% | -2.1% | Peer-reviewed paper, New England Journal of Medicine9 |
The table shows the highest dose in each trial; the lower doses also lowered weight more than placebo, by smaller amounts.9,4 In TRIUMPH-1, the average change was -17.6% on 4 mg and -23.7% on 9 mg.4
Two trials in adults with diabetes, both published in The Lancet, found a larger average weight change on every retatrutide dose than on placebo.11,12 TRIUMPH-2, measured at week 80, enrolled adults with type 2 diabetes and a body-mass index of 27 kg/m2 or higher.11 The 40-week TRANSCEND-T2D-1 enrolled adults whose type 2 diabetes was inadequately controlled by diet and exercise alone.12
Which Conditions Has Retatrutide Been Tested For?
Retatrutide has been tested in adults with obesity, in adults with diabetes, and in people with knee osteoarthritis or sleep apnea.4,11,10 Among the 574 TRIUMPH-1 participants who had knee osteoarthritis, knee pain scores fell more on each of the three retatrutide doses than on placebo.4 Pain was rated on the WOMAC pain score, on which a higher score means worse pain; the score changed by -3.2, -3.5 and -3.6 on the three doses, against -1.9 on placebo.4
Two randomized, placebo-controlled trials in the New England Journal of Medicine gave retatrutide to adults with moderate-to-severe obstructive sleep apnea and a body-mass index of at least 27.10
In TRIUMPH-1-OSA, in adults without type 2 diabetes, the average change in the apnea-hypopnea index (AHI) at 80 weeks was -22.9 on 4 mg, -34.3 on 9 mg and -31.7 on 12 mg, against -9.9 on placebo, in events per hour.10 In TRIUMPH-2-OSA, in adults with type 2 diabetes, the changes were -19.2 on 4 mg, -24.7 on 9 mg and -25.4 on 12 mg, against -10.3 on placebo.10
How to Find and Join Retatrutide Clinical Trials
Retatrutide clinical trials are listed on ClinicalTrials.gov, among them TRIUMPH-1 and NCT07232719; the registry gives each trial’s purpose, who may take part, its locations and phone numbers.13,4,14
- Search the registry. Look up retatrutide on ClinicalTrials.gov or with the FDA’s clinical trials search tool.2
- Check who may take part. Each record says who may participate.13
- Contact the study. Records list locations and phone numbers for more details.13
- Talk to your provider first. Learn about the risks and potential benefits before you take part.13
One study as an example. The record of the retatrutide study NCT07232719 lists who may take part:14
- adults aged 18 years and older;14
- a body-mass index (BMI) of 30 kilograms per square meter (kg/m2) or more, or 27 kg/m2 or more with a weight-related condition such as high blood pressure, sleep apnea or heart disease;14
- at least one unsuccessful attempt to lose weight by dieting.14
Among others, the study excludes:14
- people with type 1 or type 2 diabetes, and people who have had or plan weight-loss surgery;14
- anyone whose self-reported body weight changed by more than 5 kg (11 pounds) within 90 days before screening;14
- anyone who has taken weight-loss drugs, over-the-counter ones included, within 90 days before screening.14
Check each trial’s own record for its rules, as in the second step above.
What Does Taking Part in a Retatrutide Trial Involve?
Some people in a placebo-controlled retatrutide trial receive a placebo instead of the drug.14 The study NCT07232719 has a placebo group, and one of its measures is the percent change in body weight from baseline to week 56.14
The FDA notes that an investigational product may or may not be effective, and that its use may cause serious side effects that were not expected.2
Before you join, ask the study team what the chance is that you will receive placebo, and what the study pays for.
Eli Lilly Retatrutide Early Access and the FDA’s Expanded Access Route
Outside clinical trials, the FDA’s potential pathway to an investigational drug such as retatrutide is expanded access, sometimes called compassionate use, and Eli Lilly says it may provide retatrutide this way in rare situations.1,2,15 It is for a patient with a serious or life-threatening condition who cannot join a trial and has no comparable or satisfactory therapy.2
The FDA says the licensed physician, the IRB and the company, for retatrutide Eli Lilly, all need to agree that expanded access is appropriate for you, even if you meet the criteria under the law and FDA regulations.2,1
On its medical information page about retatrutide, Eli Lilly says that in rare situations, when people cannot join a clinical trial and have exhausted all available medical options, it may provide the investigational medicine as expanded access, in coordination with a requesting physician.15
Lilly’s listed criteria include an age of 18 years or older, and refractory obesity, which Lilly defines as a BMI of 35 kg/m2 or more despite adherence to and tolerance of treatment with the highest available dose of chronic weight management therapy.15 They also include two or more serious or life-threatening obesity-related complications for which the patient already receives standard care.15
The patient must be unable to join an ongoing trial of retatrutide or a comparable investigational medicine, and must have discussed all standard treatment options, bariatric surgery included.15 Lilly says patients with a medical contraindication to retatrutide are excluded.15
How a physician requests retatrutide expanded access from Lilly:
- Start with your treating physician. Lilly says requests are initiated by the treating physician on the patient’s behalf, and that patients should go to their treating physician rather than contact Lilly directly.15
- Lilly reviews the request. Lilly says it evaluates expanded access requests case by case, and that availability depends on geography, product supply and a detailed assessment of each patient’s eligibility.15
- If Lilly approves it, the physician signs and applies. Lilly says the treating physician must complete a letter of agreement and apply to the regulatory agency, such as the FDA, as sponsor of a patient-specific investigational new drug (IND) application for expanded access.15
- The physician obtains IRB approval. Lilly lists institutional review board (IRB) approval among the treating physician’s requirements.15
- The physician receives and dispenses the medicine. Lilly says it provides the product at no cost through the expanded access program, that the physician as sponsor handles its receipt, storage and dispensing, and that direct-to-patient shipping is not available.15
When Will Retatrutide Be Available?
Retatrutide has no approval or launch date yet: it is still an investigational drug, and launch depends on finishing its trials and regulatory review.3,2,1 Three Phase III trials of retatrutide, TRIUMPH-1, TRIUMPH-2 and TRANSCEND-T2D-1, have published their results.4,11,12
Where retatrutide stands on the way to approval:
- What the FDA has done: it has approved no drug that contains retatrutide, and it has warned companies that sold it directly to consumers.3
- Lilly’s filing plan: in a news release on its investor site, Eli Lilly said it plans to submit retatrutide for U.S. approval in Q1 2027.16 Lilly said it is first completing the Chemistry, Manufacturing, and Controls (CMC) data package required for a Biologics License Application (BLA).16
- After a potential approval: Lilly says expanded access to retatrutide will end after potential FDA approval and commercial availability.15
How Much Does Retatrutide Cost?
Retatrutide has no legitimate retail price, because selling it for human use is illegal.3,1
In a clinical trial, many studies pay for the intervention and any research-related tests and visits, and some may pay research-related travel and lodging costs, such as parking or meals.17 Participants, or their insurers, still pay for their regular health care, and each study’s informed consent form describes its payments and costs.17
For a patient who receives it through expanded access, the FDA notes there may be costs not covered by private insurance or Medicare.2
Can a Provider Prescribe Retatrutide, or a Pharmacy Compound It?
No: outside a clinical trial or expanded access, there is no retatrutide product a provider can prescribe, because no FDA-approved drug contains it, and no pharmacy can lawfully compound it.3,2
The FDA has warned telehealth companies for marketing unapproved drugs such as retatrutide, ingredient distributors for selling it to compounders, and outsourcing facilities for repackaging it.3
Is It Safe to Buy Retatrutide Peptide Online?
No: retatrutide products sold to consumers online are unapproved drugs of unknown quality that may be harmful, and the FDA urges consumers not to buy them.3 Such products have been falsely labeled “for research purposes” or “not for human consumption” and sold directly to consumers for human use, with dosing instructions.3
In a warning letter to one seller, the FDA said that labels such as “Research Use Only” did not stop the products from being drugs intended for human use.18
For illegally marketed semaglutide and tirzepatide, the FDA warns that products may be counterfeit, may contain the wrong or harmful ingredients, and may hold too little, too much or no active ingredient at all.3
What Can You Take Now Instead of Retatrutide?
Semaglutide and tirzepatide both lowered body weight more than placebo in placebo-controlled trials of adults with overweight or obesity without diabetes.5,6,7,8 Wegovy (semaglutide) and Zepbound (tirzepatide) are indicated, with a reduced-calorie diet and more physical activity, to reduce excess body weight and keep it off long term.7,8 Both labels cover adults with obesity, and adults with overweight and at least one weight-related condition.7,8
| Medicine tested | Who took part | Dose | Length | Average change in body weight | With placebo |
|---|---|---|---|---|---|
| Semaglutide | 1961 adults with overweight or obesity, without diabetes | 2.4 mg once weekly | 68 weeks | -14.9% | -2.4%5 |
| Tirzepatide | 2539 adults with obesity, or overweight with a weight-related complication, without diabetes | 15 mg once weekly | 72 weeks | -20.9% | -3.1%6 |
The table’s figures come from trials of semaglutide and tirzepatide and should not be assumed to apply to compounded versions; the next section explains how those differ from Wegovy and Zepbound.
How Compounded Semaglutide and Tirzepatide Differ From Wegovy and Zepbound
Compounded semaglutide and tirzepatide are not FDA approved, and the FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed.3 Compounding, as the FDA describes it, is generally a practice in which a licensed pharmacist or a licensed physician combines, mixes or alters ingredients of a drug to create a medication tailored to the needs of an individual patient. Unlike a generic drug, which the FDA approves as therapeutically equivalent to a brand-name drug, a compounded drug is not approved by the FDA.19
What a Telezen MD GLP-1 Plan Includes
Every Telezen MD GLP-1 plan includes a physician consultation, provider monitoring, compounded GLP-1 medication and free, expedited shipping.
Like every compounded drug, the plan’s medication is not FDA approved, and the FDA says a compounded drug should only be used when a patient’s medical needs cannot be met by an FDA-approved drug.3
To start, see what each plan includes on the Telezen MD GLP-1 therapy page. At the physician consultation, ask whether an approved medicine such as Wegovy or Zepbound could meet your needs.
Side Effects, Risks and Who Should Not Take Retatrutide, Semaglutide or Tirzepatide
Gastrointestinal side effects, such as nausea and diarrhea, were the most common with retatrutide in its trials, and were mostly mild to moderate where their severity was reported.9,4,11,12 Two Phase 3 trials, TRIUMPH-4 and TRIUMPH-1-OA, in adults without diabetes who had painful knee osteoarthritis and a body-mass index of at least 27 found serious adverse events more common with retatrutide than with placebo.20
Side Effects in the Retatrutide Trials
- TRIUMPH-2, in adults with type 2 diabetes and a BMI of 27 kg/m2 or higher: nausea affected 28% of people on the 12 mg dose and diarrhea 34%, against 8% and 13% on placebo.11
- Stopping treatment in TRIUMPH-2: more people stopped treatment for good on 9 mg (12%) and 12 mg (8%) than on 4 mg (4%) or placebo (5%), counting stops for side effects and deaths together.11
- TRANSCEND-T2D-1, a 40-week trial in adults whose type 2 diabetes was inadequately controlled by diet and exercise alone: 2 to 5% of people on retatrutide stopped because of side effects, against 0% on placebo.12
- Heart rate: in the 48-week Phase II trial, heart rate rose with the dose, peaked at 24 weeks and declined afterwards.9
In TRIUMPH-2, hypotension affected 6% of people on 12 mg against under 1% on placebo, and dysesthesia 7% against 1%.11 Hypotension is low blood pressure, a reading of 90/60 or lower. Dysesthesia is a set of symptoms around unusual touch-based sensations, which can feel unexpected, unpleasant, painful or just strange.
Who One Retatrutide Study Excludes
The retatrutide study NCT07232719 excludes, among others, people who have:14
- a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2);14
- had a heart attack, a stroke, or a hospital stay for unstable angina or congestive heart failure in the past 90 days;14
- Class IV congestive heart failure, or a history of chronic or acute pancreatitis.14
Semaglutide and Tirzepatide: Warnings on the Labels
The Wegovy and Zepbound labels say they must not be used by people with a personal or family history of MTC or with MEN2.8,7 In rodents, semaglutide and tirzepatide caused thyroid C-cell tumors, and whether they do so in humans is unknown.8,7
- Pregnancy: both labels say the medicine may cause fetal harm and should be stopped when pregnancy is recognized, Wegovy’s when it is used for weight reduction.8,7
- Pancreatitis and gallbladder disease: the Wegovy label says acute pancreatitis has been seen with GLP-1 receptor agonists, and acute gallbladder disease occurred in clinical trials.8
- Severe stomach and bowel reactions: the Zepbound label says use has been linked to gastrointestinal adverse reactions, sometimes severe, and is not recommended in severe gastrointestinal disease.7
- Allergy: Wegovy should not be used with a known hypersensitivity to semaglutide or its ingredients, nor Zepbound with a known serious hypersensitivity to tirzepatide or its ingredients.8,7
- Common side effects: in the main semaglutide trial, nausea and diarrhea led the list; in the main tirzepatide trial, gastrointestinal events did, mostly mild to moderate in both.5,6
The FDA has received reports of adverse events related to compounded semaglutide and tirzepatide, and says they are likely underreported, because state-licensed pharmacies that are not outsourcing facilities do not have to report them.3 Read Telezen MD’s important safety information before you start.
How Does Retatrutide Compare With Semaglutide and Tirzepatide?
Retatrutide adds the glucagon receptor to the GIP and GLP-1 receptors that tirzepatide acts on, while semaglutide acts on GLP-1 receptors.4,7,8
Results from separate placebo-controlled trials should not be read as a head-to-head comparison. For a fuller comparison, see retatrutide vs tirzepatide vs semaglutide.
What to Keep in Mind About the Research
TRIUMPH-1 and TRIUMPH-2 were both funded by Eli Lilly.4,11
TRIUMPH-1’s result, in adults with obesity and without diabetes over 80 weeks, should not be assumed to hold for other groups or for longer use.4
Questions to Ask a Provider Before Starting a GLP-1 Medication
Bring these questions to a provider before you start a GLP-1 medication or look for a retatrutide trial:
- Is a GLP-1 medication a fit for my health history and my goals?
- Does my personal or family history, such as MTC, MEN2 or pancreatitis, rule one out?
- Which side effects should I watch for, and what should I do if they happen?
- How will we judge whether it is working, and when will we review it?
- If I start a weight-loss medication now, how would that affect a retatrutide trial later?
When you are ready, see what a Telezen MD GLP-1 plan includes and start there.
Frequently Asked Questions
How do you get retatrutide?
Through a clinical trial, or through expanded access, a pathway for a serious or life-threatening condition with no comparable or satisfactory therapy, which a licensed physician, an institutional review board and the company must all agree to.
Is retatrutide FDA approved?
No. The FDA says retatrutide is not a component of any FDA-approved drug and has not been found safe and effective for any condition.
Does retatrutide work for weight loss?
In TRIUMPH-1, an 80-week trial of adults with obesity without diabetes published in the New England Journal of Medicine, body weight changed by an average of -25.0% on the 12 mg dose, against -3.9% on placebo.
When will retatrutide be available?
Not yet: it is considered an investigational drug, still in clinical trials, and has not been found safe and effective for any condition.
Can I get retatrutide through Eli Lilly early access?
Expanded access is a potential pathway for a patient with a serious or life-threatening condition who cannot join a clinical trial and has no comparable or satisfactory therapy; the physician, an institutional review board and the company must all agree that it is appropriate.
How much does retatrutide cost?
Retatrutide has no legitimate retail price, because no one can legally sell it for human use. Many clinical studies pay for the intervention and research-related tests and visits; through expanded access, there may be costs that insurance does not cover.
Can you buy retatrutide online?
Not legally or safely: the FDA urges consumers not to buy unapproved drugs containing retatrutide that are sold to consumers, which are of unknown quality and may be harmful.
Can a provider prescribe retatrutide, or a pharmacy compound it?
Outside a clinical trial or expanded access, no: no FDA-approved drug contains retatrutide, and it cannot be used in compounding under federal law.
Sources
- What to know about retatrutide, www.lilly.com. https://www.lilly.com/news/stories/what-to-know-about-retatrutide
- Expanded Access | Information for Patients | FDA, U.S. Food and Drug Administration, 2026. https://www.fda.gov/news-events/expanded-access/expanded-access-information-patients
- FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss | FDA, U.S. Food and Drug Administration, 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity., The New England journal of medicine, 2026. https://pubmed.ncbi.nlm.nih.gov/42814954/
- Once-Weekly Semaglutide in Adults with Overweight or Obesity., The New England journal of medicine, 2021. https://pubmed.ncbi.nlm.nih.gov/33567185/
- Tirzepatide Once Weekly for the Treatment of Obesity., The New England journal of medicine, 2022. https://pubmed.ncbi.nlm.nih.gov/35658024/
- ZEPBOUND (tirzepatide) injection, for subcutaneous use – prescribing information, U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217806s013lbl.pdf
- WEGOVY (semaglutide) injection, for subcutaneous use – prescribing information, U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215256s024lbl.pdf
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial., The New England journal of medicine, 2023. https://pubmed.ncbi.nlm.nih.gov/37366315/
- Retatrutide Once Weekly for Treatment of Obstructive Sleep Apnea., The New England journal of medicine, 2026. https://pubmed.ncbi.nlm.nih.gov/42904878/
- Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial., Lancet (London, England), 2026. https://pubmed.ncbi.nlm.nih.gov/42810372/
- Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial., Lancet (London, England), 2026. https://pubmed.ncbi.nlm.nih.gov/42250575/
- Finding a Clinical Trial | National Institutes of Health (NIH), National Institutes of Health. https://www.nih.gov/health-information/nih-clinical-research-trials-you/finding-clinical-trial
- Study Details | NCT07232719 | A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight | ClinicalTrials.gov, clinicaltrials.gov. https://clinicaltrials.gov/study/NCT07232719
- Is there an expanded access program for retatrutide?, medical.lilly.com, 2026. https://medical.lilly.com/us/products/answers/is-there-an-expanded-access-program-for-retatrutide-416668
- Lilly’s triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C | Eli Lilly and Company, investor.lilly.com. https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional
- Learn About Studies | ClinicalTrials.gov, clinicaltrials.gov. https://clinicaltrials.gov/study-basics/learn-about-studies
- Gram Peptides – 721806 – 03/31/2026 | FDA, U.S. Food and Drug Administration, 2026. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gram-peptides-721806-03312026
- Compounding and the FDA: Questions and Answers | FDA, U.S. Food and Drug Administration, 2025. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
- Retatrutide Once Weekly in Adults with Knee Osteoarthritis Pain and Obesity., The New England journal of medicine, 2026. https://pubmed.ncbi.nlm.nih.gov/43001755/
Disclaimer
This article is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Telezen MD services are available only to patients who qualify following an online medical evaluation with a licensed healthcare provider. Results vary by individual. Compounded medications prescribed through Telezen MD are compounded by 503A FDA-regulated pharmacies. Compounded medications are not reviewed or approved by the FDA for safety or efficacy. Statements on this page have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare professional before beginning any new medical treatment. If you experience any adverse effects, contact your provider immediately.

